• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向 HSP90 可增强胰腺癌细胞对 PD-1 阻断的敏感性。

Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade.

机构信息

DAMP Laboratory, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong China.

Department of Surgery, UT Southwestern Medical Center, Dallas, Texas USA.

出版信息

Oncoimmunology. 2022 Apr 25;11(1):2068488. doi: 10.1080/2162402X.2022.2068488. eCollection 2022.

DOI:10.1080/2162402X.2022.2068488
PMID:35496499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9045827/
Abstract

Interferon gamma (IFNG/IFNγ)-induced adaptive immune resistance remains a challenge for tumor therapy. We observed that the chaperone heat shock protein 90 (HSP90) stabilizes the transcription factor signal transducer and activator of transcription 1 (STAT1), resulting in IFNγ-induced expression of immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1/CD274). Pharmacological inhibition of HSP90 enhances the efficacy of programmed cell death 1 (PDCD1/PD-1) targeting immunotherapy in suitable mouse models without any toxicity.

摘要

干扰素 γ(IFNG/IFNγ)诱导的适应性免疫抵抗仍然是肿瘤治疗的一个挑战。我们观察到伴侣热休克蛋白 90(HSP90)稳定转录因子信号转导和转录激活因子 1(STAT1),导致 IFNγ 诱导的免疫抑制吲哚胺 2,3-双加氧酶 1(IDO1)和程序性死亡配体 1(PD-L1/CD274)的表达。HSP90 的药理学抑制增强了合适的小鼠模型中针对程序性细胞死亡 1(PDCD1/PD-1)的靶向免疫疗法的疗效,而没有任何毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9695/9045827/c86b3292ef39/KONI_A_2068488_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9695/9045827/c86b3292ef39/KONI_A_2068488_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9695/9045827/c86b3292ef39/KONI_A_2068488_F0001_OC.jpg

相似文献

1
Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade.靶向 HSP90 可增强胰腺癌细胞对 PD-1 阻断的敏感性。
Oncoimmunology. 2022 Apr 25;11(1):2068488. doi: 10.1080/2162402X.2022.2068488. eCollection 2022.
2
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.SIRT7 缺失通过 MEF2D 调控程序性细胞死亡配体 1 增加肝癌细胞中检查点抑制剂的疗效。
Gastroenterology. 2020 Feb;158(3):664-678.e24. doi: 10.1053/j.gastro.2019.10.025. Epub 2019 Oct 31.
3
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.CDK1/2/5 抑制克服了 IFNG 介导的胰腺癌适应性免疫抵抗。
Gut. 2021 May;70(5):890-899. doi: 10.1136/gutjnl-2019-320441. Epub 2020 Aug 14.
4
HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy.热休克蛋白90介导γ干扰素诱导的对抗程序性死亡蛋白1免疫疗法的适应性抗性。
Cancer Res. 2022 May 16;82(10):2003-2018. doi: 10.1158/0008-5472.CAN-21-3917.
5
HSP90 as an emerging barrier to immune checkpoint blockade therapy.热休克蛋白90作为免疫检查点阻断疗法的新障碍。
Oncoscience. 2022 Apr 22;9:20-22. doi: 10.18632/oncoscience.554. eCollection 2022.
6
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.用于检查点阻断免疫疗法的潜在生物标志物及治疗策略。
Tumour Biol. 2016 Apr;37(4):4251-61. doi: 10.1007/s13277-016-4812-9. Epub 2016 Jan 16.
7
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.联合阻断 IL6 和 PD-1/PD-L1 信号通路可消除肿瘤微环境中它们免疫抑制作用的相互调节。
Cancer Res. 2018 Sep 1;78(17):5011-5022. doi: 10.1158/0008-5472.CAN-18-0118. Epub 2018 Jul 2.
8
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.鉴定选择性色氨酸 2,3-双加氧酶-1(IDO1)催化抑制剂 EOS200271/PF-06840003 支持 IDO1 作为 PD-(L)1 阻断疗法耐药的关键机制。
Mol Cancer Ther. 2018 Dec;17(12):2530-2542. doi: 10.1158/1535-7163.MCT-17-1104. Epub 2018 Sep 19.
9
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.通过 eIF4F-STAT1-PD-L1 轴对黑色素瘤肿瘤免疫逃逸的翻译调控。
Nat Med. 2018 Dec;24(12):1877-1886. doi: 10.1038/s41591-018-0217-1. Epub 2018 Oct 29.
10
IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.IFN-γ 促进胰腺癌中的上皮-间充质转化和 PD-L1 的表达。
J Surg Res. 2019 Aug;240:115-123. doi: 10.1016/j.jss.2019.02.038. Epub 2019 Mar 27.

引用本文的文献

1
Hsp90 and Isoform-Selective Inhibitors as Sensitizers for Cancer Immunotherapy.热休克蛋白90(Hsp90)及亚型选择性抑制剂作为癌症免疫治疗的增敏剂
Pharmaceuticals (Basel). 2025 Jul 10;18(7):1025. doi: 10.3390/ph18071025.
2
Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment.代谢守门员:利用肿瘤衍生代谢物优化肿瘤微环境中基于 T 细胞的免疫治疗效果。
Cell Death Dis. 2024 Oct 26;15(10):775. doi: 10.1038/s41419-024-07122-6.
3
Susceptibility of polymorphisms to Kawasaki disease and immunoglobulin therapy resistance in southern Chinese children.

本文引用的文献

1
HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy.热休克蛋白90介导γ干扰素诱导的对抗程序性死亡蛋白1免疫疗法的适应性抗性。
Cancer Res. 2022 May 16;82(10):2003-2018. doi: 10.1158/0008-5472.CAN-21-3917.
2
Immunogenic cell stress and death.免疫原性细胞应激和死亡。
Nat Immunol. 2022 Apr;23(4):487-500. doi: 10.1038/s41590-022-01132-2. Epub 2022 Feb 10.
3
Interferon-γ: teammate or opponent in the tumour microenvironment?干扰素-γ:肿瘤微环境中的队友还是对手?
中国南方儿童中多态性对川崎病及免疫球蛋白治疗抵抗的易感性
Heliyon. 2024 Mar 12;10(6):e27699. doi: 10.1016/j.heliyon.2024.e27699. eCollection 2024 Mar 30.
4
Interactions of IDO and the Kynurenine Pathway with Cell Transduction Systems and Metabolism at the Inflammation-Cancer Interface.吲哚胺2,3-双加氧酶(IDO)和犬尿氨酸途径在炎症-癌症界面与细胞转导系统及代谢的相互作用。
Cancers (Basel). 2023 May 24;15(11):2895. doi: 10.3390/cancers15112895.
5
Dialog beyond the Grave: Necrosis in the Tumor Microenvironment and Its Contribution to Tumor Growth.超越生死的对话:肿瘤微环境中的坏死及其对肿瘤生长的贡献。
Int J Mol Sci. 2023 Mar 9;24(6):5278. doi: 10.3390/ijms24065278.
6
The Role of Immunotherapy in Pancreatic Cancer.免疫疗法在胰腺癌中的作用。
Curr Oncol. 2022 Sep 23;29(10):6864-6892. doi: 10.3390/curroncol29100541.
7
Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy.靶向热休克蛋白 90 治疗癌症:联合治疗的最新进展。
Cells. 2022 Aug 17;11(16):2556. doi: 10.3390/cells11162556.
Nat Rev Immunol. 2022 Mar;22(3):158-172. doi: 10.1038/s41577-021-00566-3. Epub 2021 Jun 21.
4
Challenges and Opportunities for Pancreatic Cancer Immunotherapy.胰腺癌免疫治疗的挑战与机遇。
Cancer Cell. 2020 Dec 14;38(6):788-802. doi: 10.1016/j.ccell.2020.08.004. Epub 2020 Sep 17.
5
CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.CDK1/2/5 抑制克服了 IFNG 介导的胰腺癌适应性免疫抵抗。
Gut. 2021 May;70(5):890-899. doi: 10.1136/gutjnl-2019-320441. Epub 2020 Aug 14.
6
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.干扰素-γ诱导黑色素瘤中 PD-L1 的表达依赖于 p53 表达。
J Exp Clin Cancer Res. 2019 Sep 11;38(1):397. doi: 10.1186/s13046-019-1403-9.
7
The Challenge for Development of Valuable Immuno-oncology Biomarkers.免疫肿瘤学有价值的生物标志物的发展挑战。
Clin Cancer Res. 2017 Sep 1;23(17):4970-4979. doi: 10.1158/1078-0432.CCR-16-3063.
8
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.癌症免疫疗法的原发性、适应性和获得性耐药性。
Cell. 2017 Feb 9;168(4):707-723. doi: 10.1016/j.cell.2017.01.017.
9
MYC regulates the antitumor immune response through CD47 and PD-L1.MYC 通过 CD47 和程序性死亡受体配体 1(PD-L1)调节抗肿瘤免疫反应。
Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. Epub 2016 Mar 10.
10
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.PD-L1 是 HIF-1α 的一个新型直接靶标,其在低氧环境下的阻断增强了 MDSC 介导的 T 细胞激活。
J Exp Med. 2014 May 5;211(5):781-90. doi: 10.1084/jem.20131916. Epub 2014 Apr 28.